Mantle Cell Lymphoma Insights

FDA Approves AstraZeneca's Calquence for Untreated Lymphoma Patients

Author

Liam Ball
January 23, 2025

Exclusive Report

Understanding Mantle Cell Lymphoma: Breaking Down the Medical Terms

Want to better understand Mantle Cell Lymphoma (MCL)? Our latest guide, created in collaboration with AllMyHealth, the platform that supports rare disease communities, provides a clear overview of MCL and breaks down key medical terms to help you navigate this complex condition with confidence.

Click below to read the full guide and empower yourself with knowledge today.

View the Full Report

The report is available for free online on the AllMyHealth website.

www.allmyhealth.io/report

AllMyHealth Logo

Top Stories

FDA Approves AstraZeneca's Calquence for Untreated Lymphoma Patients

AstraZeneca's Calquence has been approved by the FDA for treating untreated mantle cell lymphoma, offering a new treatment option for patients. This approval is based on clinical trial results showing the drug's effectiveness in this patient group.

Read More →

CALQUENCE Plus Chemoimmunotherapy Approved for Untreated Lymphoma Patients in US

The FDA has approved CALQUENCE (acalabrutinib) combined with chemoimmunotherapy for treating patients with previously untreated mantle cell lymphoma. This new treatment option aims to improve outcomes for those suffering from this condition.

Read More →

Calquence Combo Approved for Untreated Mantle Cell Lymphoma Patients

The FDA has approved a combination therapy featuring Calquence for previously untreated mantle cell lymphoma, offering a new treatment option. This approval is based on clinical trial results showing improved outcomes for patients with this condition.

Read More →

AstraZeneca's Calquence Gains FDA Approval for Rare Blood Cancer Treatment

AstraZeneca's drug Calquence has received FDA approval for treating mantle cell lymphoma, a rare blood cancer. This approval offers a new treatment option for patients with this condition, potentially improving their outcomes.

Read More →

Latest Research

Recent developments in the treatment of mantle cell lymphoma include the addition of Bortezomib for Injection, a proteasome inhibitor, which has been indicated for adult patients with this condition, as announced by Camber Pharmaceuticals (Pharmacy times, 2025). Meanwhile, the diagnostic process for lymphomas has been highlighted as challenging, especially when atypical immune phenotypes are present, which can be associated with aggressive clinical behavior and poor prognosis (Zhang et al., 2025). Furthermore, Brentuximab Vedotin (BV), an antibody-drug conjugate targeting CD30, has been reviewed for its efficacy in lymphoma treatments, including mantle cell lymphoma. It has been found that the clinical benefit of BV does not necessarily correlate with CD30 expression levels, suggesting its potential as a targeted treatment approach across a wide range of CD30 expression levels (Chen & Zhang, 2025). These advancements underscore the importance of personalized medicine and the need for comprehensive diagnostic evaluations in the management of mantle cell lymphoma.